Zobrazeno 1 - 10
of 901
pro vyhledávání: '"Phase I clinical trial"'
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 5853-5861 (2024)
Woo Kyung Chung,1 Inseung Jeon,1 In-Jin Jang,1 Seung-Yong Seong,2 Seon Ae Han,3 Kyung-Sang Yu1 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea; 2Department of
Externí odkaz:
https://doaj.org/article/89f6e0b19a8d46f9b3063ba13be1f0d1
Autor:
Anke Pagnon, Christophe Carre, Marion Aguirre, Emilie Chautard, Sophie Gimenez, Franck Raynal, Emmanuel Feroldi, Paul Scott, Kayvon Modjarrad, Manuel Vangelisti, Nathalie Mantel
Publikováno v:
EBioMedicine, Vol 108, Iss , Pp 105332- (2024)
Summary: Background: Yellow fever (YF), a mosquito-borne acute viral haemorrhagic illness, is endemic to many tropical and subtropical areas of Africa and Central and South America. Vaccination remains the most effective prevention strategy; however,
Externí odkaz:
https://doaj.org/article/2a2747ae42384d60b9b6678996455730
Publikováno v:
Thoracic Cancer, Vol 15, Iss 5, Pp 427-433 (2024)
Abstract Introduction The prognosis of patients with advanced or metastatic sarcoma is very poor, and a new strategy for patients who fail systemic treatment is urgently required. Apatinib is a small molecule tyrosine kinase inhibitor of VEGFR‐2, w
Externí odkaz:
https://doaj.org/article/544dfa9bd63a4576a5b1d449ae643012
Autor:
SHI Liping, ZOU Chong
Publikováno v:
Zhongguo linchuang yanjiu, Vol 36, Iss 11, Pp 1713-1717 (2023)
Objective To explore and analyze the reasons on the failure of subjects screening in Phase Ⅰ clinical trials. Methods The subjects screening data of 10 Phase I clinical trials conducted from February 2019 to December 2020 were summarized, and the r
Externí odkaz:
https://doaj.org/article/7525ea9cf90a4fb0b6d80e65d8593f0e
Autor:
Koichi Goto, Yoshimasa Shiraishi, Haruyasu Murakami, Hidehito Horinouchi, Ryo Toyozawa, Masayuki Takeda, Makiko Uno, Nigel Crawford, Joseph McGill, Takeshi Jimbo, Masato Ishigami, Gensuke Takayama, Shintaro Nakayama, Shoichi Ohwada, Makoto Nishio
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 7090-7104 (2023)
Abstract Background Tyrosine kinase inhibitors (TKIs) are effective for the treatment of non‐small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth factor receptor (EGFR), but responses are not durable as tumors d
Externí odkaz:
https://doaj.org/article/4ccb84ac3b1f40d88e709e0bae4a3f6b
Publikováno v:
BMC Medical Research Methodology, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Combinations of drugs are becoming increasingly common in oncology treatment. In some cases, patients can benefit from the interaction between two drugs, although there is usually a higher risk of developing toxicity. Due to drug
Externí odkaz:
https://doaj.org/article/dd528fdec5144de98752bc12268f40e0
Publikováno v:
Pharmaceuticals, Vol 17, Iss 3, p 278 (2024)
Mistletoe lectins (ML) have cytotoxic and immunomodulating properties, and subcutaneously applied mistletoe products (MP) containing ML have approval for supportive cancer treatment. MP are also given off-label intravenously, but data about pharmacok
Externí odkaz:
https://doaj.org/article/8da5da4ce3b64bb78b2fcb0e88bd97f4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Statistical Theory and Related Fields, Vol 5, Iss 4, Pp 288-302 (2021)
Toxicity study, especially in determining the maximum tolerated dose (MTD) in phase I clinical trial, is an important step in developing new life-saving drugs. In practice, toxicity levels may be categorised as binary grades, multiple grades, or in a
Externí odkaz:
https://doaj.org/article/c9ffb3309b4647258b9d871dcf07a614